Abstract
While androgen ablation remains a mainstay for advanced prostate cancer therapy, nearly all patients will inevitably develop disease escape with time. Upon the development of castration-resistant prostate cancer, other androgen-axis-targeted treatments may be added in an effort to starve the disease of its androgen signaling. Nevertheless, additional androgen-pathway resistance usually develops to these novel hormonal therapies. In this review, we will discuss the resistance mechanisms to modern androgen-axis modulators and how these alterations can influence a patient’s response to novel hormonal therapy. We conceptualize these resistance pathways as three broad categories: (1) reactivation of androgen/AR-signaling, (2) AR bypass pathways, and (3) androgen/AR-independent mechanisms. We highlight examples of each, as well as potential therapeutic approaches to overcome these resistance mechanisms.
Original language | English (US) |
---|---|
Article number | 29 |
Pages (from-to) | 1-10 |
Number of pages | 10 |
Journal | Current Urology Reports |
Volume | 17 |
Issue number | 4 |
DOIs | |
State | Published - Apr 1 2016 |
Externally published | Yes |
Bibliographical note
Publisher Copyright:© 2016, Springer Science+Business Media New York.
Keywords
- Androgen receptor
- Biomarker
- Prostate cancer
- Resistance
- Splice variants